EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

CT-Guided Iodine-125 Seed Implantation Combined with Anlotinib for Recurrent Retroperitoneal Undifferentiated Pleomorphic Sarcoma: A Case Report

Li Chen, Sheng Lin

Case Reports in Oncology · 20.08.2026 · 19 (1) · 1585-1593

DOI: 10.1159/cro/abzag025 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 20.08.2026. Verfasst von Li Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Undifferentiated sarcoma is a rare and highly aggressive malignancy with a high risk of postoperative recurrence and limited treatment options. The management of recurrent retroperitoneal sarcoma remains challenging. CT-guided iodine-125 (I-125) seed implantation provides localized brachytherapy, while anlotinib, a multi-target tyrosine kinase inhibitor, has demonstrated efficacy in soft-tissue sarcomas. However, evidence regarding their combined use is limited. Case Presentation: We report a patient with recurrent retroperitoneal undifferentiated sarcoma following prior surgical resection. The recurrence was identified on follow-up imaging as a retroperitoneal mass with irregular margins and heterogeneous enhancement, and was deemed unresectable due to its proximity to critical structures. After multidisciplinary evaluation, the patient underwent CT-guided I-125 radioactive seed implantation for local tumor control. The procedure was successfully completed without complications. Subsequently, the patient received oral anlotinib therapy. The combined treatment was well tolerated, with no severe adverse events observed. Serial follow-up imaging demonstrated a reduction in tumor size and sustained local disease control, indicating a favorable therapeutic response.

Conclusion

This case suggests that CT-guided I-125 seed implantation combined with anlotinib may be a safe and effective therapeutic option for patients with recurrent retroperitoneal undifferentiated sarcoma who are not candidates for surgery. Further studies are warranted to confirm these findings.

Schlagwörter

Stichwörter der Autor:innen

AnlotinibBrachytherapyIodine-125 seed implantationRetroperitoneal tumorUndifferentiated pleomorphic sarcoma

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • Department of Oncology, Wusheng County People's Hospital, Guang'an, China.

Zitieren

APA

Chen, L., & Lin, S. (2026). CT-Guided Iodine-125 Seed Implantation Combined with Anlotinib for Recurrent Retroperitoneal Undifferentiated Pleomorphic Sarcoma: A Case Report. Case Reports in Oncology, 19(1), 1585-1593. https://doi.org/10.1159/cro/abzag025

Vancouver

Chen L, Lin S. CT-Guided Iodine-125 Seed Implantation Combined with Anlotinib for Recurrent Retroperitoneal Undifferentiated Pleomorphic Sarcoma: A Case Report. Case Reports in Oncology. 2026;19(1):1585-1593. doi:10.1159/cro/abzag025

BibTeX
@article{Chen2026,
  author = {Chen, Li and Lin, Sheng},
  title = {CT-Guided Iodine-125 Seed Implantation Combined with Anlotinib for Recurrent Retroperitoneal Undifferentiated Pleomorphic Sarcoma: A Case Report},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {1585--1593},
  doi = {10.1159/cro/abzag025}
}
Kostenlos starten →